Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05822830 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 751
- Enrollment target
NCT05822830 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 751 participants.
The verdict
NCT05822830, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 751 participants
- Enrollment target
Study Summary
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 751 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2024-11-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05822830
The ClinicalTrials.gov registry entry for NCT05822830 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 751 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT05822830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05822830 about?
NCT05822830 is a clinical study titled "A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities". The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
What is the current status of trial NCT05822830?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 751 participants. The study started on 2023-04-21. Estimated completion is 2024-11-13.
What interventions are being tested in trial NCT05822830?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT05822830?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.